Core Viewpoint - Zhendemedical has experienced a significant stock price increase of 38.96% over the past seven days, closing at 59.49 CNY per share with a market capitalization of 15.851 billion CNY [1] Group 1: Company Overview - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, is located in Shaoxing, Zhejiang Province. The company specializes in the production, research, and sales of medical dressings [1] - The revenue composition of Zhendemedical includes: 43.04% from surgical infection control, 20.46% from basic care, 18.59% from ostomy and modern wound care, 10.75% from pressure treatment and fixation, 6.58% from infection control protection, and 0.58% from other sources [1] Group 2: Shareholder Information - The top circulating shareholder of Zhendemedical is the "Zhaoshang Core Competitiveness Mixed A" fund, which increased its holdings by 581,000 shares to a total of 3.4286 million shares, representing 1.29% of circulating shares. The fund has gained approximately 10.3888 million CNY in floating profit today and 54.2754 million CNY during the seven-day increase [2] - The "Zhaoshang Core Competitiveness Mixed A" fund was established on April 13, 2022, with a current scale of 2.993 billion CNY. It has achieved a year-to-date return of 21.25% and a one-year return of 18.18% [2] Group 3: Fund Manager Information - The fund manager of "Zhaoshang Core Competitiveness Mixed A" is Zhu Hongyu, who has a total tenure of 14 years and 151 days. The fund's total asset scale is 4.964 billion CNY, with the best return during his tenure being 57.7% and the worst being -12.86% [3][5] Group 4: Fund Holdings - Another fund, "Zhaoshang Social Responsibility Mixed A," holds 1.367 million shares of Zhendemedical, accounting for 2.96% of the fund's net value. This fund has gained approximately 4.142 million CNY in floating profit today and 21.6396 million CNY during the seven-day increase [4] - The "Zhaoshang Social Responsibility Mixed A" fund was established on April 26, 2023, with a current scale of 974 million CNY. It has achieved a year-to-date return of 29.24% and a one-year return of 25.23% [4]
振德医疗股价涨5.37%,招商基金旗下1只基金位居十大流通股东,持有342.86万股浮盈赚取1038.88万元